PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation

• Peiyang Gao

Beilstein J. Nanotechnol. 2025, 16, 1914–1930, doi:10.3762/bjnano.16.133

• PEG; immunogenicity; lipid nanoparticles; PEG alternatives; PEG lipids; therapeutic delivery; Review Introduction Lipid nanoparticles (LNPs) have become a promising platform in modern nanomedicine, especially for delivering genetic payloads such as mRNA and siRNA. These nanoscale particles can

• strategies in LNP-based drug delivery systems, approaches are being explored. These include integrating functional groups into PEG lipids for ligand conjugation and improved cell-specific targeting, as well as developing PEG alternatives to mitigate anti-PEG antibody associated immunogenicity [7][8]. This

• lower than anti-PEG IgM during the repeated administrations. While it is argued that PEG alternatives may still elicit immune recognition through other pathways, this analysis is insightful to support that DMG-PEOZ2k lipid induces a markedly milder IgM response. Notably, this reduction in anti-polymer